Acute Hematological Toxicity during Cranio-Spinal Proton Therapy in Pediatric Brain Embryonal Tumors.
acute hematological toxicity
childhood brain tumors
craniospinal irradiation
embryonal tumors
proton therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Mar 2022
24 Mar 2022
Historique:
received:
06
02
2022
revised:
21
03
2022
accepted:
22
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Embryonal tumors represent a heterogeneous entity of brain tumors that need a multidisciplinary treatment including cranio-spinal irradiation (CSI), with a known impact on the acute toxicity. Proton therapy (PT) boasts a reduction in acute hematological toxicity. We retrospectively examined 20 pediatric patients affected by high-risk medulloblastoma and other rare embryonal brain tumors subjected to CSI with PT from September 2016 to April 2020. Before CSI, all patients received induction chemotherapy, and three patients additionally received two high-dose courses with thiotepa, followed by an autologous haemopoietic stem cell transplantation. We recorded the total white blood cell count, absolute neutrophil count, platelets, and hemoglobin levels for all patients during PT. Leucocytes and neutrophils decreased directly after the beginning of treatment, reaching a complete recovery at the end of treatment. Hemoglobin values remained constant over the treatment course. The median platelet value decreased until reaching a plateau around halfway through therapy, followed by a slow increase. No cases of febrile neutropenia or severe infections were reported. No treatment discontinuation due to hematological toxicity was necessary. CSI with PT was proven to be safe in this setting of pediatric patients. Our study showed that despite all patients having undergone chemotherapy prior to irradiation, no serious hematological toxicity was reported at the end of the treatment with PT, and, therefore, no treatment was discontinued or delayed.
Sections du résumé
BACKGROUND
BACKGROUND
Embryonal tumors represent a heterogeneous entity of brain tumors that need a multidisciplinary treatment including cranio-spinal irradiation (CSI), with a known impact on the acute toxicity. Proton therapy (PT) boasts a reduction in acute hematological toxicity.
METHODS
METHODS
We retrospectively examined 20 pediatric patients affected by high-risk medulloblastoma and other rare embryonal brain tumors subjected to CSI with PT from September 2016 to April 2020. Before CSI, all patients received induction chemotherapy, and three patients additionally received two high-dose courses with thiotepa, followed by an autologous haemopoietic stem cell transplantation. We recorded the total white blood cell count, absolute neutrophil count, platelets, and hemoglobin levels for all patients during PT.
RESULTS
RESULTS
Leucocytes and neutrophils decreased directly after the beginning of treatment, reaching a complete recovery at the end of treatment. Hemoglobin values remained constant over the treatment course. The median platelet value decreased until reaching a plateau around halfway through therapy, followed by a slow increase. No cases of febrile neutropenia or severe infections were reported. No treatment discontinuation due to hematological toxicity was necessary.
CONCLUSIONS
CONCLUSIONS
CSI with PT was proven to be safe in this setting of pediatric patients. Our study showed that despite all patients having undergone chemotherapy prior to irradiation, no serious hematological toxicity was reported at the end of the treatment with PT, and, therefore, no treatment was discontinued or delayed.
Identifiants
pubmed: 35406425
pii: cancers14071653
doi: 10.3390/cancers14071653
pmc: PMC8997073
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Acta Oncol. 2014 Sep;53(9):1158-64
pubmed: 24913151
J Clin Neurosci. 2012 Nov;19(11):1541-4
pubmed: 22981874
Acta Neuropathol. 2016 Jun;131(6):821-31
pubmed: 27040285
Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):726-735
pubmed: 33243479
Neuro Oncol. 2016 Oct 1;18(suppl_5):v1-v75
pubmed: 28475809
Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1008-16
pubmed: 11958896
Eur J Cancer. 2006 May;42(8):1120-8
pubmed: 16632346
Pediatr Blood Cancer. 2013 Dec;60(12):2031-5
pubmed: 23852767
Int J Radiat Oncol Biol Phys. 1988 Jun;14(6):1103-7
pubmed: 3384715
Ann Oncol. 2010 May;21 Suppl 5:v252-6
pubmed: 20555092
Radiology. 1975 Jan;114(1):155-62
pubmed: 813276
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):343-355
pubmed: 28603224
J Neurooncol. 2017 Sep;134(2):309-315
pubmed: 28577033
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Clin Oncol. 2015 Oct 1;33(28):3199-212
pubmed: 26169616
Pediatr Blood Cancer. 2015 May;62(5):776-83
pubmed: 25704363
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1319-39
pubmed: 7713791
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):277-84
pubmed: 23433794
Lancet Oncol. 2016 Mar;17(3):287-298
pubmed: 26830377
Lancet Oncol. 2019 Mar;20(3):e155-e166
pubmed: 30842059
Curr Probl Cancer. 2015 Sep-Oct;39(5):292-6
pubmed: 26293689
J Clin Oncol. 2009 Feb 1;27(4):566-71
pubmed: 19075266
Pract Radiat Oncol. 2022 Mar-Apr;12(2):155-162
pubmed: 34929404
Radiother Oncol. 2017 Apr;123(1):112-118
pubmed: 28283192
Radiother Oncol. 1998 Jul;48(1):23-7
pubmed: 9756168
Curr Opin Pediatr. 2019 Feb;31(1):28-34
pubmed: 30531222
Eur J Cancer. 1995;31A(3):302-7
pubmed: 7540401